These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. Moosmann N; Heinemann V Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070 [TBL] [Abstract][Full Text] [Related]
5. Current status of capecitabine in the treatment of colorectal cancer. Rothenberg ML Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635 [TBL] [Abstract][Full Text] [Related]
6. [Recent results of irinotecan therapy in colorectal cancer]. Láng I; Hitre E Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572 [TBL] [Abstract][Full Text] [Related]
7. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725 [TBL] [Abstract][Full Text] [Related]
9. The role of new agents in the treatment of colorectal cancer. Folprecht G; Köhne CH Oncology; 2004; 66(1):1-17. PubMed ID: 15031593 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin. Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749 [TBL] [Abstract][Full Text] [Related]
11. Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. Maniadakis N; Pallis A; Fragoulakis V; Prezerakos P; Georgoulias V Curr Med Res Opin; 2007 Sep; 23(9):2251-7. PubMed ID: 17706002 [TBL] [Abstract][Full Text] [Related]
12. [IFL]. Yamazaki K; Yoshino T; Boku N Gan To Kagaku Ryoho; 2006 Jul; 33(7):907-10. PubMed ID: 16835478 [TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748 [TBL] [Abstract][Full Text] [Related]
14. Irinotecan in the treatment of colorectal cancer: clinical overview. Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497 [TBL] [Abstract][Full Text] [Related]
16. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715 [TBL] [Abstract][Full Text] [Related]
17. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. Grothey A; Sargent D; Goldberg RM; Schmoll HJ J Clin Oncol; 2004 Apr; 22(7):1209-14. PubMed ID: 15051767 [TBL] [Abstract][Full Text] [Related]
18. Current treatments and future perspectives in colorectal and gastric cancer. Wilke HJ; Van Cutsem E Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459 [TBL] [Abstract][Full Text] [Related]
19. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685 [TBL] [Abstract][Full Text] [Related]
20. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer. Fisher MD Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365 [No Abstract] [Full Text] [Related] [Next] [New Search]